I-Mab

IMAB

US44975P1030

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.8 ^USD	-0.55%		0.00%	-5.26%

Apr. 18	Verastem Names John Hayslip as Chief Medical Officer	MT
Apr. 15	I-Mab Announces Chief Medical Officer Changes	CI

I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab

February 06, 2024

I-mab Biopharma (Hangzhou) Co., Ltd. announced that it will receive equity funding for $19 million from returning investor I-Mab on February 7, 2024. The transaction is expected to be close by the end of March 2024.

Latest news about I-Mab

Verastem Names John Hayslip as Chief Medical Officer	Apr. 18	MT
I-Mab Announces Chief Medical Officer Changes	Apr. 15	CI
I-Mab Completes Business Divestiture in China	Apr. 02	MT
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	Apr. 01	CI
I-Mab Announces Executive Resignation	Apr. 01	CI
Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating	Mar. 18	MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating	Mar. 15	MT
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	Feb. 15	RE
I-Mab Divests China Operations, Shifts Focus to US Market	Feb. 08	MT
ADRs Close Higher, Renalytix PLC Climbs 96.9%	Feb. 08	DJ
Biotech firm I-Mab to divest China operations, shift focus to US	Feb. 07	RE
Biotech firm I-Mab to divest China operations	Feb. 07	RE
I-Mab Announces Board Changes , Effective February 10, 2024	Feb. 07	CI
I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab	Feb. 06	CI
I-Mab Announces Chief Financial Officer Changes	Feb. 06	CI
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading	Jan. 11	MT
ADRs Slump; FLJ Group Declines 21%	Jan. 02	DJ
I-Mab(NasdaqGM:IMAB) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
I-Mab Says FDA Grants Breakthrough Therapy Designation for Felzartamab to Treat Kidney Disease	Nov. 02	MT
I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy	Nov. 02	CI
I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023	23-10-16	CI
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503	23-10-10	CI
AbbVie Terminates $3 Billion Cancer Drug Deal With Biotech Firm I-Mab	23-09-25	MT
Global markets live: Ford, China Evergrande, KKR, Moderna, Booking...	23-09-25

Chart I-Mab

Duration

Period

More charts

Company Profile

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Companyâs pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.8 USD

Average target price

7.25 USD

Spread / Average Target

+302.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
I-MAB	-5.26%	145M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+26.24%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+14.55%	231B
NOVARTIS AG	+5.27%	200B
ROCHE HOLDING AG	-9.00%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

I-Mab

Equities

IMAB

US44975P1030

Pharmaceuticals

I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab

Latest news about I-Mab

Chart I-Mab

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals